BioAge Labs' BGE-102 trial shows promising results in Phase 1 trials.

BioAge Labs' BGE-102, a treatment for metabolic diseases, showed positive results in its Phase 1 trial. The drug was well-tolerated and achieved high target engagement, suppressing IL-1β cytokine by 90-98%. BGE-102 also exhibited high brain penetration, exceeding target levels in cerebrospinal fluid at Day 14. The company plans to expand the trial to include cohorts in participants with obesity and elevated hsCRP, with data expected in H1 2026.